Ginkgo Bioworks secured a project agreement under BARDA’s BioMaP‑Consortium worth up to $22.2 million to develop scalable, cost‑reducing approaches for monoclonal antibody manufacturing aimed at filovirus countermeasures (Ebola and Sudan viruses). The collaboration brings together Ginkgo, Advanced BioScience Laboratories, Isolere Bio, NeuImmune, ProteoNic, and Emory University, which provided the 1C3/1C11 antibody cocktail. The project targets end‑to‑end process innovations — from discovery to high‑yield expression and downstream processing — intended to strengthen U.S. domestic biomanufacturing readiness for high‑consequence pathogens. Who: Ginkgo, BARDA, Emory; why it matters: public‑private investment in rapid, cost‑effective mAb production addresses national biosecurity priorities and could set manufacturing standards for future pandemic countermeasures.